Insomnia and depressive symptoms in patients with Parkinson's disease

Caap‐Ahlgren, Marianne; Dehlin, Ove

doi:10.1016/s0167-4943(00)00087-x

Cited by 92 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous cross-sectional studies in PD patients with insomnia do not allow us to draw conclusions on the causal relationship between affective symptoms and insomnia [8, 19–21] . However, one can imagine that having a chronic, progressive disease, which results in increasing disability over time, can cause negative cognitions and emotions, leading to psychological and physiological arousal and subsequent sleep problems.…”

Section: Discussionmentioning

confidence: 99%

“…Insomnia, depression and anxiety often co-occur in PD [8, 19–21] , and insomnia is a symptom of both depression and some anxiety disorders, for instance generalized anxiety disorder [41] . This may raise the question whether the associations we found can be explained by the fact that insomnia is an integral part of affective disorders.…”

Section: Discussionmentioning

confidence: 99%

“…Alternatively, affective disorders may cause a disturbance of sleep [15, 18] . In PD patients, an association between insomnia and both depression [8, 19–21] and anxiety [21] has been found in cross-sectional studies, but such investigations do not allow for determination of temporal order.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease

Rutten

Vriend

Werf

et al. 2017

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Introduction Anxiety, depression and insomnia are each common and frequently co-occur in Parkinson’s disease (PD) patients. Yet, little is known about their temporal relationship. In this study, we tested two hypotheses: i) insomnia predicts an increase in symptoms of depression or anxiety and ii) anxiety or depression at baseline predicts the occurrence of insomnia in PD patients six months later. Methods We used longitudinal data from an ongoing prospective cohort study in early-stage, still medication-naïve PD patients. Primary outcome measures were: anxiety symptoms (measured with the State-Trait Anxiety Inventory score), depressive symptoms (measured with the 15-item Geriatric Depression Scale score) and insomnia (defined as a score ≥ 2 on item 1.7 of the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale). We performed linear and logistic regression analyses, correcting for baseline value of the respective outcome variable. Results We included 361 subjects. The was not an association between baseline insomnia and subsequent anxiety (B(SE)=1.75 (1.81), p=0.33) and depression (B(SE)=0.49 (0.31), p=0.11). However, baseline symptoms of both anxiety (B(SE)=0.02 (0.01), p=0.001) and depression (B(SE)=0.15 (0.05), p<0.01) independently predicted insomnia at follow-up. Conclusion Insomnia is not a risk factor for subsequent symptoms of affective disorders, but symptoms of anxiety and depression predict future insomnia in unmedicated, early-stage PD patients. This suggests that affective symptoms are a risk factor or prodrome for the development of insomnia in PD, and therefore a target for prevention research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease

Rutten

Vriend

Werf

et al. 2017

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

show abstract

“…{7} Yet another study showed that insomnia was associated with greater pain and depressive symptoms. {8} In addition, short sleep duration (< or = 6 hours) and early morning awakening are strongly correlated with fatigue in PD. {9}…”

Section: Introductionmentioning

confidence: 99%

Associations of Sleep Disturbance Symptoms With Health-Related Quality of Life in Parkinson’s Disease

Avidan¹,

Diaz²,

Bordelon³

et al. 2013

JNP

View full text Add to dashboard Cite

We examined associations of different sleep disturbance symptoms with health-related quality of life (HRQOL) in 153 adults with Parkinson’s disease (PD). PD patients reported more snoring, sleep inadequacy, daytime somnolence, and sleep maintenance problems than the general population (p<0.001). Symptoms having the broadest and strongest unique associations with generic HRQOL (8 scales; 2 composites of SF-36) were daytime somnolence (5 scales; 1 composite), sleep initiation (8 scales; 2 composites), and awakening short of breath or with headache (6 scales; 2 composites) (p’s<0.05). Associations of selected sleep disturbance symptoms – some unanticipated – suggest that assessing specific symptoms is worthwhile in clinical care.

show abstract

“…Выра-женность проявлений депрессии может колебаться в за-висимости от моторного состояния и усиливаться в пери-оды «выключения» [31]. Больные БП и сопутствующей депрессией имеют бóльший риск когнитивных рас-стройств [32][33][34][35][36], более быстрого прогрессирования мо-торных проявлений нарушений и инвалидизации [35], больший риск развития психотических нарушений [37], худшее качество жизни [38][39][40], бóльшие страдания уха-живающих лиц [41].…”

unclassified

Comorbid states in Parkinson’s disease: an effect of MAO-B inhibitors

Katunina

2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

обзоры Болезнь Паркинсона (БП) относится к категории двигательных расстройств (англ. movement disorders), од-нако заболевание никогда не проявляется исключительно моторной симптоматикой. Классические двигательные проявления (брадикинезия, ригидность, тремор, посту-ральные нарушения) обычно сочетаются с 10-12 немо-торными симптомами [1], побочными эффектами дофа-минергических препаратов, коморбидностью, в том числе «случайной», которая может быть представлена не связан-ными с БП соматическими или неврологическими забо-леваниям. Такая полиморбидность ведет к одновремен-ному назначению большого количества лекарственных препаратов, что не только снижает приверженность боль-ных к лечению и увеличивает их материальные затраты, но и способствует резкому возрастанию риска развития нежелательных побочных эффектов, что зачастую влечет за собой использование еще большего количества лекар-ственных препаратов. Это объясняет актуальность вопро-сов переносимости и безопасности противопаркинсони- Comorbid states in Parkinson's disease: an effect of MAO-B inhibitorsn.v. titovA, e.A. KAtuninA, n.n. SotniKovAPirogov russian national research medical university, moscow the comorbidity in Parkinson's disease (Pd), which is closely related to the tolerability of antiparkinsonian drugs, is analyzed. the authors present the results of the studies that have confirmed the greater safety of rasagiline compared to dopamine receptor agonists in elderly patients. the effects of rasagiline, including combinations of this drug with antidepressants, on depression in Pd and the low risk of the serotonin syndrome caused by these combinations are considered. the studies demonstrated the effect of rasagiline on fatigue and cognitive functions in Pd patients are described. Single cases of the development of impulsivecompulsive disorders in patients treated with rasagiline are presented.

show abstract

Insomnia and depressive symptoms in patients with Parkinson's disease

Cited by 92 publications

References 32 publications

The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease

The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease

Associations of Sleep Disturbance Symptoms With Health-Related Quality of Life in Parkinson’s Disease

Comorbid states in Parkinson’s disease: an effect of MAO-B inhibitors

Contact Info

Product

Resources

About